Skip to main content
SpringerLink
Log in

Adis Summary of Research: Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder

  • Adis Summary of Research
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

In patients with attention deficit hyperactivity disorder (ADHD), norepinephrine reuptake inhibitors like atomoxetine may show mild effectiveness in addressing both inattention and hyperactivity/impulsivity. The relative efficacy of branded extended-release viloxazine (viloxazine ER) compared to generic atomoxetine remains unknown. This Adis Summary of Research summarizes the efficacy and tolerability of a voluntary switch from atomoxetine to viloxazine ER, prompted by adverse events or inadequate response, based on a retrospective chart review conducted in the USA. The switch improved ADHD symptoms and tolerability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Reference

  1. Price MZ, Price RL. Extended-release viloxazine compared with atomoxetine for attention deficit hyperactivity disorder. CNS Drugs. 2023;37(7):655–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Yahiya Y. Syed

Authors
  1. Yahiya Y. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yahiya Y. Syed.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of Interest

Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Syed, Y.Y. Adis Summary of Research: Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder. Drugs Ther Perspect 40, 139–140 (2024). https://doi.org/10.1007/s40267-024-01067-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-024-01067-8

Search

Navigation